ASHAP: A regimen for cytoreduction of refractory or recurrent Hodgkin's disease

Blood

Volumn 93, Issue 11, 1999, Pages 3632-3636

  Rodriguez, J ^a   Rodriguez, M A ^a   Fayad, L ^a   McLaughlin, P ^a   Swan, F ^a   Sarris, A ^a   Romaguera, J ^a   Andersson, B ^a   Cabanillas, F ^a   Hagemeister, F B ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CHLORMETHINE; CISPLATIN; CYTARABINE; DACARBAZINE; DOXORUBICIN; METHYLPREDNISOLONE SODIUM SUCCINATE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONTINUOUS INFUSION; DRUG RESPONSE; FEMALE; HODGKIN DISEASE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0033153007     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v93.11.3632.411k13_3632_3636     Document Type: Article

References (21)

1. Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, Green MR, Gottlieb A, Peterson BA: Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327:1478, 1992
2. Yuen AR, Horning SJ: Hodgkin's disease: Management of first relapse. Oncology 10:233, 1996
3. Fisher RI, DeVita VT, Hubbard SP, Simon R, Young RC: Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse. Ann Intern Med 90:761, 1979
4. Canellos GP: The second chance for advanced Hodgkin's disease. J Clin Oncol 10:175, 1992
5. Longo DL, Duffey PL, Young RC, Hubbard SM, Ihde DC, Glatstein E, Phares JC, Jaffe ES, Urba WJ, DeVita Jr VT: Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: The low probability for cure. J Clin Oncol 10:210, 1992
6. Armitage JO, Bierman PJ, Vose JM, Anderson JR, Weisenburger DD, Kessinger A, Reed EC, Vaughan WP, Coccia PF, Purtilo DT: Autologous bone marrow transplant for patients with relapsed Hodgkin's disease. Am J Med 91:605, 1991
7. Jagannath S, Dicke KA, Armitage JO, Cabanillas FF, Horwitz LJ, Vellekoop L, Zander AR, Spitzer G: High dose cyclophosphamide, carmustine and etoposide, and autologous bone marrow transplantation for relapsed Hodgkin's disease. Ann Intern Med 104:163, 1986
8. Reece DE, Connors JM, Spinelli JJ, Barnett MJ, Fairey RN, Klingemann HG, Nantel SH, O'Reilly S, Shepherd JD, Sutherland HJ, Voss N, Chan KW, Phillips GL: Intensive therapy with cyclophosphamide, carmustine, etoposide, ± cisplatin, autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy. Blood 83:1193, 1994
9. Horning SJ, Chao NJ, Negrin RS, Hoppe RT, Long GD, Hu WW, Wong RM, Brown BW, Blume KG: High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: Analysis of the Stanford University results and prognostic indices. Blood 89:801, 1997
10. Velasquez WS, Pereira AR, Dunphy F, Broun Jr, GO, Petruska PJ, Broun ER: ASHAP ± ABMT: An effective strategy for relapsing and refractory Hodgkin's disease (HD). Blood 86:825a, 1995 (abstr)
11. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457, 1958
12. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG: Design and analysis of randomized clinical trials requiring prolonged observation of each patient II analysis and examples. Br J Cancer 35:1, 1977
13. Armitage P, Berry G: Statistical Methods in Medical Research (ed 2). Oxford, UK, Blackwell Scientific, 1987, pp 125-132
14. Kessinger A, Bierman PJ, Vose JM, Armitage JO: High-dose cyclophosphamide, carmustine, and etoposide followed by autologous peripheral stem cell transplantation for patients with relapsed Hodgkin's disease. Blood 77:2322, 1991
15. Rapoport AP, Rowe JM, Kouides PA, Duerst RA, Abboud CN, Liesveld JL, Packman CH, Eberly S, Sherman M, Tanner MA, Constine LS, DiPersio JF: One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: Value of pretransplant disease status for predicting outcome. J Clin Oncol 11:2351, 1993
16. Viviani S, Santoro A, Negretti E, Bonfante V, Valagussa P, Bonadonna G: Salvage chemotherapy in Hodgkin's disease. Results in patients relapsing more than twelve months after first complete remission. Ann Oncol 1:123, 1990
17. Santoro A, Viviani S, Villarreal CJR, Bonfante V, Delfino A, Valagussa P, Bonadorna G: Salvage cheomotherapy in Hodgkin's disease irradiation failures: Superiority of doxorubicin-containing regimens over MOPP. Cancer Treat Rep 70:343, 1986
18. Richards MA, Wasman JH, Man T, Ganesan TS, Barnett MJ, Wrigley PF, Lister TA: EVA treatment for recurrent or unresponsive Hodgkin's disease. Cancer Chemother Pharmacol 18:51, 1986
19. Pfreunschuh MG, Schoppe WD, Fuchs KH: Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): A multicenter trial of the German Hodgkin's Study Group. Cancer Treat Rep 71:1203, 1987
20. Brusamolino E, Orlandi E, Canevari A, Morra E, Castelli G, Alessandrino EP, Pagnucco G, Bernasconi P, Astori C, Lazzarino M: Results of CAV regimen (CCNU, melphalan, and VP-16) as third line salvage regimen for Hodgkin's disease. Ann Oncol 5:427, 1994
21. Hagemeister FB, Tannir N, McLaughlin P, Salvador P, Riggs S, Velasquez WS, Cabanillas F: MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease. J Clin Oncol 5:556, 1987